Advertisement
Screener

NeoGenomics, Inc. (NEO) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.9 / 5 stars · 42/72 Roast Me

NeoGenomics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

NeoGenomics, Inc. (NEO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2023-05-09

  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-03-31 was 0.00%.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
  • NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2023-03-310.00%
10-Q · filed 2023-05-09
2022-12-310.00%
10-K · filed 2023-02-24
2022-09-300.00%
10-Q · filed 2022-11-08
2022-06-300.00%
10-Q · filed 2022-08-09
2022-03-310.00%
10-Q · filed 2022-05-09
2021-12-310.00%
10-K · filed 2023-02-24
2021-09-300.00%
10-Q · filed 2021-11-04
2021-06-300.00%
10-Q · filed 2021-08-09
2021-03-310.00%
10-Q · filed 2021-05-06
2020-12-310.00%
10-K · filed 2023-02-24
2020-09-300.00%
10-Q · filed 2020-10-29
2020-06-300.00%
10-Q · filed 2020-07-31
2020-03-310.00%
10-Q · filed 2020-04-29
2019-12-310.00%
10-K · filed 2022-02-25
2019-09-300.00%
10-Q · filed 2019-11-13
2019-06-300.00%
10-Q · filed 2019-08-07
2019-03-310.00%
10-Q · filed 2019-05-08
2018-12-310.00%
10-K · filed 2021-02-25
2018-09-300.00%
10-Q · filed 2018-11-06
2018-06-300.00%
10-Q · filed 2018-08-06
2018-03-310.00%
10-Q · filed 2018-05-08
2017-12-310.00%
10-K · filed 2020-02-28
2017-09-300.00%
10-Q · filed 2017-11-13
2017-06-300.00%
10-Q · filed 2017-08-07
2017-03-310.00%
10-Q · filed 2017-05-09
2016-12-310.00%
10-K · filed 2019-02-26
2016-09-300.00%
10-Q · filed 2016-11-07
2016-06-300.00%
10-Q · filed 2016-08-05
2015-12-310.00%
10-K · filed 2018-03-13
2014-12-310.00%
10-K · filed 2017-03-14
2013-12-310.00%
10-K · filed 2016-04-18
2012-12-310.00%
10-K · filed 2015-03-03
2011-12-310.00%
10-K · filed 2014-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
20/20 Biolabs, Inc. (AIDX)United States$0.005B